Rodney Hicks

FDG PET/CT Prognostic Markers in Patients with Advanced Melanoma Treated with Ipilimumab and Nivolumab.

Amir Iravani, Roslyn Wallace, Serigne N Lo, Anna Galligan, Alison M Weppler, Rodney J Hicks, Shahneen Sandhu

Journal article  |  2023  |  Radiology

Background Despite improved response to combined ipilimumab and nivolumab (hereafter, IpiNivo) treatment for advanced melanoma, ma..

Facts and Myths About Stage Migration: Should the Will Rogers Phenomenon Ride off into the Distance?

Stefano Fanti, Elisabetta Lalumera, Rodney Hicks

Journal article  |  2023  |  Eur Urol Oncol

Phase Ib/II Trial of BRAF and EGFR inhibition in BRAFV600E metastatic colorectal cancer and other cancers: EVICT (Erlotinib and Vemurafenib In Combination Trial).

Lavinia Tan, Ben Tran, Jeanne Tie, Ben Markman, Sumi Ananda, Niall C Tebbutt, Michael Michael, Emma Link, Stephen Q Wong, Sushma Chandrashekar, Jerick Guinto, David Ritchie, Rachel Koldej, Benjamin J Solomon, Grant A McArthur, Rodney J Hicks, Peter Gibbs, Sarah-Jane Dawson, Jayesh Desai

Journal article  |  2023  |  Clin Cancer Res

PURPOSE: BRAF V600E mutant metastatic colorectal cancer represents a significant clinical problem, with combination approaches bei..

Single-nuclei and bulk-tissue gene-expression analysis of pheochromocytoma and paraganglioma links disease subtypes with tumor microenvironment (vol 13, 6262, 2022)

Magnus Zethoven, Luciano Martelotto, Andrew Pattison, Blake Bowen, Shiva Balachander, Aidan Flynn, Fernando J Rossello, Annette Hogg, Julie A Miller, Zdenek Frysak, Sean Grimmond, Lauren Fishbein, Arthur S Tischler, Anthony J Gill, Rodney J Hicks, Patricia LM Dahia, Roderick Clifton-Bligh, Karel Pacak, Richard W Tothill

Journal article  |  2023  |  NATURE COMMUNICATIONS

The original version of this Article contained an error in Supplementary Data 5, as column A listing the gene names was misaligned..

A 2022 International Survey on the Status of Prostate Cancer Theranostics.

Thomas Beyer, Johannes Czernin, Lutz Freudenberg, Frederik Giesel, Marcus Hacker, Rodney J Hicks, Bernd J Krause

Journal article  |  2023  |  J Nucl Med

Growing interest in PSMA imaging using [68Ga]- or [18F]-labeled ligands and PSMA-based radioligand therapy (RLT) of prostate cance..

Immune and genomic biomarkers of immunotherapy response in cancer of unknown primary

Atara Posner, Tharani Sivakumaran, Andrew Pattison, Dariush Etemadmoghadam, Niko Thio, Colin Wood, Krista Fisher, Samantha Webb, Anna DeFazio, Nicholas Wilcken, Bo Gao, Christos S Karapetis, Madhu Singh, Ian M Collins, Gary Richardson, Christopher Steer, Mark Warren, Narayan Karanth, Andrew Fellowes, Stephen B Fox, et al.

Journal article  |  2023  |  JOURNAL FOR IMMUNOTHERAPY OF CANCER

BACKGROUND: Cancer of unknown primary (CUP) is a heterogeneous group of metastatic cancers where a primary tissue of origin (TOO) ..

Perspectives on joint EANM/SNMMI/ANZSNM practice guidelines/procedure standards for [18F]FDG PET/CT imaging during immunomodulatory treatments in patients with solid tumors.

E Lopci, N Aide, A Dimitrakopoulou-Strauss, L Dercle, A Iravani, RD Seban, C Sachpekidis, O Humbert, O Gheysens, AWJM Glaudemans, WA Weber, AD Van den Abbeele, RL Wahl, AM Scott, N Pandit-Taskar, RJ Hicks

Journal article  |  2022  |  Cancer Imaging

Response assessment in the context of immunomodulatory treatments represents a major challenge for the medical imaging community a..

A comparison of DNA sequencing and gene expression profiling to assist tissue of origin diagnosis in cancer of unknown primary

Atara Posner, Owen Wj Prall, Tharani Sivakumaran, Dariush Etemadamoghadam, Niko Thio, Andrew Pattison, Shiva Balachander, Krista Fisher, Samantha Webb, Colin Wood, Anna DeFazio, Nicholas Wilcken, Bo Gao, Christos S Karapetis, Madhu Singh, Ian M Collins, Gary Richardson, Christopher Steer, Mark Warren, Narayan Karanth, et al.

Journal article  |  2022  |  JOURNAL OF PATHOLOGY

Cancer of unknown primary (CUP) is a syndrome defined by clinical absence of a primary cancer after standardised investigations. G..

ImmunoPET: IMaging of cancer imMUNOtherapy targets with positron Emission Tomography: a phase 0/1 study characterising PD-L1 with 89Zr-durvalumab (MEDI4736) PET/CT in stage III NSCLC patients receiving chemoradiation study protocol.

Fiona Hegi-Johnson, Stacey E Rudd, Christian Wichmann, Tim Akhurst, Peter Roselt, Jenny Trinh, Thomas John, Lisa Devereux, Paul S Donnelly, Rod Hicks, Andrew M Scott, Daniel Steinfort, Stephen Fox, Benjamin Blyth, Sagun Parakh, Gerard G Hanna, Jason Callahan, Kate Burbury, Michael MacManus

Journal article  |  2022  |  BMJ Open

BACKGROUND: ImmunoPET is a multicentre, single arm, phase 0-1 study that aims to establish if 89Zr-durvalumab PET/CT can be used t..

The Value of the Standardized Uptake Value (SUV) and Metabolic Tumor Volume (MTV) in Lung Cancer

Rodney J Hicks

Journal article  |  2022  |  SEMINARS IN NUCLEAR MEDICINE

The diagnosis, staging and therapeutic monitoring of lung cancer were amongst the first applications for which the utility of FDG ..